Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Inventory (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Inventory for 15 consecutive years, with $30.6 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 11.27% to $30.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.6 million through Dec 2025, up 11.27% year-over-year, with the annual reading at $30.6 million for FY2025, 11.27% up from the prior year.
  • Inventory for Q4 2025 was $30.6 million at Myriad Genetics, down from $31.6 million in the prior quarter.
  • The five-year high for Inventory was $31.6 million in Q3 2025, with the low at $15.3 million in Q4 2021.
  • Average Inventory over 5 years is $23.1 million, with a median of $23.6 million recorded in 2021.
  • The sharpest move saw Inventory crashed 43.54% in 2021, then skyrocketed 46.1% in 2023.
  • Over 5 years, Inventory stood at $15.3 million in 2021, then skyrocketed by 31.37% to $20.1 million in 2022, then grew by 9.45% to $22.0 million in 2023, then grew by 25.0% to $27.5 million in 2024, then grew by 11.27% to $30.6 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $30.6 million, $31.6 million, and $28.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.